GRAIL, LLC (GRAL)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $5.21B
Last updated: Nov 17, 2026 at 11:05 AM ET
GRAIL, LLC (GRAL) Earnings: Report Dates and Results
GRAIL, LLC (GRAL) is expected to report earnings on Feb 17, 2027. In the quarter ended Sep 30, 2026, GRAIL, LLC reported EPS of -$2.21, above the -$2.78 estimate. It beat the EPS estimate in each of the last 9 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
GRAL has an expected report date of Feb 17, 2027.
GRAL Earnings Call
The latest GRAL earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Revenue for the quarter ended Sep 30, 2026 was $37.53M, up 3.7% from $36.19M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$2.21 | -$2.78 | -$2.85 - -$1.49 | +20.50% | Beat | N/A | 4 | 1 up, 0 down | Nov 4, 2026 | $37.53M |
| Jun 30, 2026 | -$2.56 | -$2.91 | -$2.97 - -$1.43 | +12.03% | Beat | N/A | 3 | 0 up, 1 down | Aug 5, 2026 | $44.69M |
| Mar 31, 2026 | -$1.37 | -$1.96 | -$2.54 - -$1.44 | +30.10% | Beat | N/A | 4 | 2 up, 0 down | May 5, 2026 | $40.78M |
| Dec 31, 2025 | -$2.44 | -$2.53 | -$2.87 - -$2.16 | +3.56% | Beat | N/A | 4 | N/A | Feb 19, 2026 | $43.60M |
| Sep 30, 2025 | -$2.46 | -$3.26 | -$3.48 - -$3.05 | +24.54% | Beat | N/A | 3 | 1 up, 0 down | Nov 12, 2025 | $36.19M |
| Jun 30, 2025 | -$3.18 | -$3.56 | -$3.68 - -$3.36 | +10.67% | Beat | N/A | 3 | N/A | Aug 12, 2025 | $35.54M |
| Mar 31, 2025 | -$3.10 | -$3.80 | -$3.80 - -$3.80 | +18.42% | Beat | N/A | 1 | 0 up, 0 down | May 13, 2025 | $31.84M |
| Dec 31, 2024 | -$2.89 | -$4.97 | N/A | +41.85% | Beat | N/A | N/A | 0 up, 0 down | Feb 20, 2025 | $38.25M |
| Sep 30, 2024 | -$3.50 | -$6.43 | N/A | +45.57% | Beat | N/A | N/A | N/A | Nov 12, 2024 | $28.65M |
| Jun 30, 2024 | -$51.06 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 13, 2024 | $31.97M |
Annual EPS
| Fiscal year ended | EPS | Change |
|---|---|---|
| Sep 30, 2026 | -$6.14 | N/A |
| Jun 30, 2026 | -$3.93 | N/A |
| Dec 31, 2025 | -$11.18 | N/A |
| Dec 31, 2024 | -$57.45 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,700 words across 13 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,703 | 13 | |
| 2026Q2 | Jun 30, 2026 | 5,800 | 13 | |
| 2026Q1 | Mar 31, 2026 | 4,480 | 13 | |
| 2025Q4 | Dec 31, 2025 | 6,161 | 12 | |
| 2025Q3 | Sep 30, 2025 | 4,398 | 10 | |
| 2025Q2 | Jun 30, 2025 | 4,713 | 12 | |
| 2025Q1 | Mar 31, 2025 | 4,678 | 9 | |
| 2024Q4 | Dec 31, 2024 | 3,060 | 7 |
2026Q3 Earnings Call
Opening remarks
GRAIL Investor Relations Investor Relations Thank you, and thank you all for joining us today. On the call are Josh Ofman, our Chief Executive Officer; Aaron Freidin, Chief Financial Officer; Sir Harpal Kumar, Chief Scientific Officer and President, Global Clinical and Medical Affairs; and Andy Partridge, Chief Growth Officer. I'll remind you that we'll be making forward-looking statements based on current expectations. It's our intent that all statements other than statements of historical facts, including statements regarding our anticipated financial results and commercial activity, will be covered by the safe harbor provisions for forward-looking statements under the federal securities laws. Forward-looking statements are subject to risks and uncertainties. Actual events or results may differ materially from those projected or discussed. All forward-looking statements are based upon currently available information, and GRAIL assumes no obligation to update these statements. To better understand the risks and uncertainties that could cause actual results to differ, we refer you to the documents that GRAIL files with the Securities and Exchange Commission, including the Risk Factors section in GRAIL's most recent annual report on Form 10-K and the quarterly report on Form 10-Q we plan to file for the third quarter of 2026. This call will also include a discussion of GAAP results and certain non-GAAP financial measures, including adjusted gross profit, adjusted gross margin, and adjusted EBITDA, which exclude certain specified items. Our non-GAAP financial measures are intended to supplement your understanding of GRAIL's financials. Reconciliations of the non-GAAP measures to the most directly comparable GAAP financial measures are available in the press release issued today, which is available on our website. With that, we turn to Josh.
Joshua Ofman CEO Thank you. Good afternoon, everyone, and thank you for joining us to review results for the third quarter of 2026 and to discuss recent business updates. GRAIL achieved multiple significant milestones this quarter, including a favorable vote for approval from the FDA's Advisory Committee and the publication of NHS-Galleri and PATHFINDER-2 results in the New England Journal of Medicine and Nature Medicine. These important clinical and regulatory milestones position us very well as we continue to progress toward future potential regulatory approval and reimbursement. As you know, we submitted our premarket approval application for Galleri to the FDA in January of this year. On September 23, the FDA convened an expert advisory committee to consider the safety, effectiveness, and overall benefit-risk profile of Galleri for screening for the early detection of multiple types of cancer in adults aged 50 years and older. Galleri is the first multi-cancer early detection test to undergo FDA review through the PMA pathway, and we were very pleased with the positive vote.
Frequently Asked Questions About GRAL
When is GRAIL, LLC's next earnings date?
GRAIL, LLC's next earnings report is expected for Feb 17, 2027.
Did GRAL beat earnings estimates last quarter?
Yes. GRAIL, LLC reported EPS of -$2.21 for the quarter ended Sep 30, 2026, above the -$2.78 estimate, a 20.50% surprise.
What EPS do analysts expect from GRAL next quarter?
The consensus EPS estimate for GRAIL, LLC for the quarter ending Dec 31, 2026 is -$2.20 from 13 analysts, with estimates from -$2.61 to -$1.44.
How often does GRAL beat earnings estimates?
GRAIL, LLC beat the EPS estimate in each of the last 9 quarters, with an average surprise of +23.03%.
GRAL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors